This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buggy, J. J. Articles by Dalrymple, S. A. Search for Related Content PubMed PubMed Citation Articles by Buggy, J. J. Articles by Dalrymple, S. A.

Research Articles: Therapeutics

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo

Celera Genomics, South San Francisco, California

Requests for reprints: Joseph J. Buggy, Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080. Phone: 650-866-6236; Fax: 650-866-6652. E-mail: drjbuggy{at}yahoo.com

CRA-024781 is a novel, broad spectrum hydroxamic acid–based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clinical trials for cancer. CRA-024781 inhibited pure recombinant HDAC1 with a K_i of 0.007 µmol/L, and also inhibited the other HDAC isozymes HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 in the nanomolar range. Treatment of cultured tumor cell lines grown in vitro with CRA-024781 resulted in the accumulation of acetylated histone and acetylated tubulin, resulting in an inhibition of tumor cell growth and the induction of apoptosis. CRA-024781 parenterally administered to mice harboring HCT116 or DLD-1 colon tumor xenografts resulted in a statistically significant reduction in tumor growth at doses that were well tolerated as measured by body weight. Inhibition of tumor growth was accompanied by an increase in the acetylation of -tubulin in peripheral blood mononuclear cells, and an alteration in the expression of many genes in the tumors, including several involved in apoptosis and cell growth. These results reveal CRA-024781 to be a novel HDAC inhibitor with potent antitumor activity. [Mol Cancer Ther 2006;5(5):1309–17]

Received 10/25/05; revised 2/ 6/06; accepted 3/ 2/06.

This article has been cited by other articles:

				S. Adimoolam, M. Sirisawad, J. Chen, P. Thiemann, J. M. Ford, and J. J. Buggy HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination PNAS, December 4, 2007; 104(49): 19482 - 19487. [Abstract] [Full Text] [PDF]

				C. A. Banuelos, J. P. Banath, S. H. MacPhail, J. Zhao, T. Reitsema, and P. L. Olive Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781 Clin. Cancer Res., November 15, 2007; 13(22): 6816 - 6826. [Abstract] [Full Text] [PDF]

				Z. A. Cao, K. E. Bass, S. Balasubramanian, L. Liu, B. Schultz, E. Verner, Y. Dai, R. A. Molina, J. R. Davis, S. Misialek, et al. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol. Cancer Ther., July 1, 2006; 5(7): 1693 - 1701. [Abstract] [Full Text] [PDF]